Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31295055 | 0.88 | TAAR1 (0.44) | TAAR1 | |
| SCHEMBL4837815 | 0.79 | HDAC1 (0.37) | — | |
| SCHEMBL20969693 | 0.78 | TAAR1 (0.53) | TAAR1 | |
| SCHEMBL11919300 | 0.77 | TAAR1 (0.47) | LMNAMAPK1HTTRAB9ATAAR1 | |
| SCHEMBL2689433 | 0.76 | ALDH1A1 (0.50) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL584542 | 0.76 | KDM4E (0.47) | ALDH1A1LMNAMAPK1HTTRAB9A | |
| SCHEMBL28154665 | 0.76 | HTR2B (0.43) | LMNAMAPK1HTTRAB9AHTR1A | |
| SCHEMBL2315500 | 0.75 | POLB (0.50) | LMNAMAPK1HTTRAB9APOLB | |
| SCHEMBL27828878 | 0.75 | ALDH1A1 (0.34) | ALDH1A1TUBB1CHRM2CHRM1CHRM3 | |
| SCHEMBL6556289 | 0.74 | CYP3A4 (0.53) | ALDH1A1HTTMEN1KMT2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105906617-B | Modulators of HEC1 activity and methods thereof | 泰纬生命科技股份有限公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-104254534-B | Modulators of HEC1 activity and methods thereof | 泰纬生命科技股份有限公司 | 2017-07-14 | — | — | CN | disclosed |
| CN-105906617-A | Modulators of HEC1 activity and methods thereof | 泰纬生命科技股份有限公司 | 2016-08-31 | — | — | CN | disclosed |
| US-8188082-B2 | 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2125823-B1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | ALDH1A1 1460/4885LMNA 3882/4885MAPK1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.